Halozyme Projects Zero to Minimal Royalty Impact From Medicare Rule
Halozyme Therapeutics announced on November 6, 2026 that it projects zero to minimal impact on royalty revenue through at least 2035 after analyzing the final Medicare Drug Price Negotiation Program rule issued by the U.S. Centers for Medicare & Medicaid Services on November 5, 2026. The assessment keeps the company’s long-range royalty outlook intact now that CMS has finalized regulations for the program starting with initial price applicability year 2029. President and CEO Helen Torley also…